Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.68 |
| ▸ | MIF | P14174 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.68 |
| ▸ | HTR2B | P41595 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43453 | 1.00 | ADRB1 (0.68) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL29586078 | 1.00 | ADRB1 (0.68) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL782546 | 1.00 | ADRB1 (0.68) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL29708001 | 1.00 | ADRB1 (0.68) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL29429681 | 1.00 | ADRB1 (0.68) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL3066472 | 0.98 | ADRB1 (0.66) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| Formic Acid SCHEMBL27966100 | 0.90 | ADRB1 (0.58) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL659099 | 0.83 | ADRB2 (0.46) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL10785909 | 0.81 | ADRB1 (0.61) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL921895 | 0.81 | ADRB1 (0.61) | ADRB1ADRA1AMIFHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106905100-B | Resolution method of chiral amine compound and intermediate thereof | 联化科技（台州）有限公司 | 2022-07-15 | — | — | CN | claimed |
| EP-2582799-B1 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL | CODEXIS INC (US) | 2017-12-20 | — | — | EP | claimed |
| CN-106905100-A | The method for splitting and its intermediate of chiral aminated compounds | 联化科技（台州）有限公司 | 2017-06-30 | — | — | CN | claimed |
| US-8852900-B2 | Biocatalysts and methods for the synthesis of (S)-3-(1-aminoethyl)-phenol | CODEXIS, INC. (US) | 2014-10-07 | — | — | US | claimed |
| US-20130089898-A1 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL | CODEXIS, INC. (US) | 2013-04-11 | — | — | US | claimed |
| WO-2011070585-A1 | PROCESSES FOR PREPARING RIVASTIGMINE, SALTS AND INTERMEDIATES THEREOF | SHODHANA LABORATORIES LIMITED (IN) | 2011-06-16 | — | — | WO | claimed |
| US-20060229315-A1 | 3-Substituted Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | GLAXOSMITHKLINE S.P.A. (IT) | 2006-10-12 | — | — | US | claimed |
| EP-1659120-A1 | 3-substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GlaxoSmithKline S.p.A. (IT) | 2006-05-24 | — | — | EP | claimed |
| US-20040180902-A1 | 3-Substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-09-16 | — | — | US | claimed |
| US-12378537-B2 | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs | CODEXIS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12305201-B2 | Engineered biocatalysts and methods for synthesizing chiral amines | CODEXIS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240026401-A1 | ENGINEERED BIOCATALYSTS AND METHODS FOR SYNTHESIZING CHIRAL AMINES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20230332115-A1 | ENGINEERED BIOCATALYSTS AND METHODS FOR SYNTHESIZING CHIRAL AMINES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-10-19 | — | — | US | disclosed |
| WO-2022159688-A9 | DEGRADERS OF GRK2 AND USES THEREOF | SONATA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20040097518-A1 | Quinoline derivatives as nk-3 antagonists | GLAXOSMITHKLINE S.P.A. (IT) | 2004-05-20 | — | — | US | disclosed |
| EP-1392644-A1 | CINNAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1351953-A1 | QUINOLINE DERIVATIVES AS NK-3 ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2003-10-15 | — | — | EP | disclosed |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | disclosed |
| WO-2002096858-A1 | CINNAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002044165-A1 | QUINOLINE DERIVATIVES AS NK-3 ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180902-A1 | 3-Substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | HRH4, HRH2, HRH3 | ADRB1 59/4885ADRA1A 147/4885MIF 2756/4885 |
| US-20040097518-A1 | Quinoline derivatives as nk-3 antagonists | KCNK3, KCNQ3, KCNN3 | ADRB1 195/4885ADRA1A 368/4885MIF 1354/4885 |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | KCNH2, KCNH3, KCNQ1 | ADRB1 424/4885ADRA1A 610/4885MIF 4550/4885 |
| US-20060229315-A1 | 3-Substituted Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | KCNK3, KCNJ2, KCNK2 | ADRB1 240/4885ADRA1A 444/4885MIF 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.